--- title: "U.S. stock market update: Curis down 14.33%, pressured by reverse stock split and SEC announcement" type: "News" locale: "en" url: "https://longbridge.com/en/news/291574939.md" description: "Curis fell 14.33%; Moderna rose 7.97%, with a transaction volume of USD 713 million; AbbVie rose 3.11%, with a transaction volume of USD 560 million; Abivax SA rose 8.58%, with a transaction volume of USD 396 million; Amgen rose 2.54%, with a market value of USD 200 billion" datetime: "2026-07-02T17:32:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291574939.md) - [en](https://longbridge.com/en/news/291574939.md) - [zh-HK](https://longbridge.com/zh-HK/news/291574939.md) generator: "portal-rs" --- # U.S. stock market update: Curis down 14.33%, pressured by reverse stock split and SEC announcement **U.S. Stock Market Midday Update** Curis, down 14.33%, with increased trading volume. Based on recent key news: 1. On July 2, Curis announced that shareholders approved a 1-for-20 reverse stock split, leading to a decline in stock price. 2. On July 2, the relative strength index (RSI) for Curis stock was 48.76, with a 75.88% decrease in stock price over the past 12 months, and the current trading price is close to the lower end of the annual trading range. 3. On July 1, the U.S. Securities and Exchange Commission issued a notice regarding information disclosure related to Curis, increasing market uncertainty. The biotechnology sector has recently shown weak performance, with increased market risk. **Top Stocks by Trading Volume in the Industry** Moderna rose 7.97%. Based on recent key news: 1. On July 1, the FDA advisory committee voted 9-0 in support of Moderna's flu vaccine mRNA-1010 for adults over 50, with the final FDA decision expected on August 5. This news boosted the stock price, with Q1 2026 revenue projected to reach $389 million, a 264% year-over-year increase. Source: MarketWatch 2. On July 1, HHS Secretary Robert F. Kennedy Jr. terminated the emergency use authorization for COVID-19 treatment drugs and medical devices, but COVID vaccines remain unaffected. This move stabilized market confidence in Moderna's vaccine. Source: CNBC 3. On July 2, CNBC's Jim Cramer praised Moderna's business prospects, stating that its new product line demonstrates a clear roadmap to profitability, although he advised waiting for a stock price pullback. This comment enhanced market optimism towards Moderna. Source: CNBC Flu vaccine support boosts market confidence. AbbVie rose 3.11%, with increased trading volume. Based on recent key news: 1. On July 3, AbbVie completed its acquisition of Apogee Therapeutics for over $10 billion, aimed at strengthening its position in the immunology field. This move pushed the stock price to a record high, currently at $259.80. Source: Zhitong Finance 2. On June 30, AbbVie achieved the fourth milestone in its collaboration with Nxera Pharma for multi-target drug development, receiving a $10 million payment. This collaboration focuses on drug development for neurological diseases, further enhancing market confidence. Source: RTTNews 3. On June 30, AbbVie's EPCORE DLBCL-4 trial results showed that combination therapy reduced the risk of disease progression by 60%, boosting investor confidence in the company's R&D capabilities. Source: Bloomberg The biotechnology industry has recently performed strongly, with significant capital inflows Abivax SA rose by 8.58%. Based on recent key news: 4. On July 2, Abivax SA announced that the underwriters had fully exercised their over-allotment option, raising $920 million. This news drove the stock price up by 5.91%. 5. On July 1, Abivax SA announced the launch of a public offering of American Depositary Shares, planning to raise $800 million to support the commercialization and clinical research of its core candidate drug obefazimod. 6. On July 1, Abivax SA resumed trading on Euronext Paris after a suspension due to pricing and investor allocation issues. The stock price rose after trading resumed. The biotechnology sector has recently performed strongly, with high investor demand. **Stocks ranked among the top in industry market capitalization** Amgen rose by 2.54%. Based on recent key news: 1. On June 30, Amgen was ordered to pay $60.6 million for patent infringement. This ruling has negatively impacted Amgen's legal risks and financial condition, leading to stock price volatility. Source: Zhitong Finance 2. On June 30, clinical trial data for Amgen's drug Tavneos was retracted, and the European Medicines Agency recommended the withdrawal of its market authorization. This event has put pressure on Amgen's drug sales and market confidence. Source: Bloomberg 3. On July 1, analysts maintained a neutral rating on Amgen and raised the target price to $303. This move reflects a cautiously optimistic attitude in the market regarding Amgen's future performance. Source: Mizuho Analyst Report on the biopharmaceutical industry facing patent challenges ### Related Stocks - [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [How Cathie Wood's fund gave us a back door to Moderna's breakthrough](https://longbridge.com/en/news/298769510.md) - [Promising Biotech Stocks To Keep An Eye On - September 12th](https://longbridge.com/en/news/298811794.md) - [Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA](https://longbridge.com/en/news/298693237.md) - [New FDA Drug Approvals - August 2026](https://longbridge.com/en/news/298751885.md) - [Weight Loss Trial Results Altering The Investment Case For Structure Therapeutics (GPCR)?](https://longbridge.com/en/news/298754574.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**